SAMHD1 and pancreatic neoplasm: Interestingly, we found significant heterogeneity in SAMHD1 expression across different tumor types, from 100% positivity for rectal cancer, through 68% in ovary, 61% in breast, 50% in NSCLC and 11% in pancreatic cancer, similar to available data from public databases, except for rectal cancer, where the distinct methodology used for its evaluation may influence in the high positivity observed.